SG11201910009UA - Variants of human bmp7 protein - Google Patents
Variants of human bmp7 proteinInfo
- Publication number
- SG11201910009UA SG11201910009UA SG11201910009UA SG11201910009UA SG 11201910009U A SG11201910009U A SG 11201910009UA SG 11201910009U A SG11201910009U A SG 11201910009UA SG 11201910009U A SG11201910009U A SG 11201910009UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indianapolis
- company
- eli lilly
- indiana
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2857—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490910P | 2017-04-27 | 2017-04-27 | |
| PCT/US2018/028496 WO2018200322A1 (fr) | 2017-04-27 | 2018-04-20 | Variants de la protéine bmp7 humaine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910009UA true SG11201910009UA (en) | 2019-11-28 |
Family
ID=62196685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910009U SG11201910009UA (en) | 2017-04-27 | 2018-04-20 | Variants of human bmp7 protein |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11466066B2 (fr) |
| EP (1) | EP3615561B1 (fr) |
| JP (1) | JP7308151B2 (fr) |
| KR (1) | KR20200012870A (fr) |
| CN (1) | CN110997708A (fr) |
| AU (1) | AU2018258100B2 (fr) |
| BR (1) | BR112019022566A2 (fr) |
| CA (1) | CA3061606A1 (fr) |
| CL (1) | CL2019003074A1 (fr) |
| CO (1) | CO2019013150A2 (fr) |
| CR (1) | CR20190539A (fr) |
| EA (1) | EA201992558A1 (fr) |
| MX (1) | MX2019012871A (fr) |
| PE (1) | PE20200385A1 (fr) |
| PH (1) | PH12019502442A1 (fr) |
| SG (1) | SG11201910009UA (fr) |
| WO (1) | WO2018200322A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101885737B1 (ko) | 2018-04-30 | 2018-08-06 | 주식회사 이지요구르트 | 요구르트발효기 및 요구르트발효기의 자동 온도제어 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008500816A (ja) | 2004-03-31 | 2008-01-17 | ゼンコー・インコーポレイテッド | 改善された性質を有するｂｍｐ−７変異体 |
| AU2007339280B2 (en) | 2006-12-21 | 2013-12-05 | Stryker Corporation | Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents |
| JP2010531135A (ja) | 2007-06-04 | 2010-09-24 | ノボ ノルディスク アクティーゼルスカブ | Ｎ−アセチルグルコサミニルトランスフェラーゼを使用したｏ結合型グリコシル化 |
| US7846428B2 (en) | 2007-10-05 | 2010-12-07 | Merial Limited | Articular cartilage gene therapy with recombinant vector encoding BMP-7 |
| US20110039773A1 (en) | 2007-12-21 | 2011-02-17 | Stryker Biotech | BMP Mutants with Decreased Susceptibility to Noggin |
-
2018
- 2018-04-20 PE PE2019002134A patent/PE20200385A1/es unknown
- 2018-04-20 EP EP18725687.0A patent/EP3615561B1/fr active Active
- 2018-04-20 MX MX2019012871A patent/MX2019012871A/es unknown
- 2018-04-20 WO PCT/US2018/028496 patent/WO2018200322A1/fr unknown
- 2018-04-20 SG SG11201910009U patent/SG11201910009UA/en unknown
- 2018-04-20 EA EA201992558A patent/EA201992558A1/ru unknown
- 2018-04-20 JP JP2019558439A patent/JP7308151B2/ja active Active
- 2018-04-20 KR KR1020197035030A patent/KR20200012870A/ko not_active Application Discontinuation
- 2018-04-20 CA CA3061606A patent/CA3061606A1/fr active Pending
- 2018-04-20 BR BR112019022566A patent/BR112019022566A2/pt unknown
- 2018-04-20 US US16/608,015 patent/US11466066B2/en active Active
- 2018-04-20 CR CR20190539A patent/CR20190539A/es unknown
- 2018-04-20 CN CN201880038790.9A patent/CN110997708A/zh active Pending
- 2018-04-20 AU AU2018258100A patent/AU2018258100B2/en active Active
-
2019
- 2019-10-25 CL CL2019003074A patent/CL2019003074A1/es unknown
- 2019-10-28 PH PH12019502442A patent/PH12019502442A1/en unknown
- 2019-11-25 CO CONC2019/0013150A patent/CO2019013150A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3615561B1 (fr) | 2024-01-10 |
| KR20200012870A (ko) | 2020-02-05 |
| EA201992558A1 (ru) | 2020-03-04 |
| BR112019022566A2 (pt) | 2020-05-19 |
| CO2019013150A2 (es) | 2020-02-28 |
| US11466066B2 (en) | 2022-10-11 |
| AU2018258100B2 (en) | 2022-04-14 |
| EP3615561C0 (fr) | 2024-01-10 |
| MX2019012871A (es) | 2021-01-08 |
| AU2018258100A1 (en) | 2019-11-14 |
| WO2018200322A1 (fr) | 2018-11-01 |
| JP7308151B2 (ja) | 2023-07-13 |
| CA3061606A1 (fr) | 2018-11-01 |
| CN110997708A (zh) | 2020-04-10 |
| PE20200385A1 (es) | 2020-02-24 |
| PH12019502442A1 (en) | 2020-10-05 |
| US20210115100A1 (en) | 2021-04-22 |
| CL2019003074A1 (es) | 2020-05-08 |
| CR20190539A (es) | 2020-03-26 |
| JP2020517706A (ja) | 2020-06-18 |
| EP3615561A1 (fr) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201803642WA (en) | Bacteria-based protein delivery |